Saturday, February 4, 2017

DOH YIELDS TO CONGRESS DENGUE VACCINE BLACKMAIL

eastwind journals21 Dec 2016 02:16 am
DOH YIELDS TO CONGRESS DENGUE VACCINE BLACKMAIL * It’s Official, US Recession is Here
DOH YIELDS TO CONGRESS DENGUE VACCINE BLACKMAIL
Vaccine Maker SANOFI Accused of Meddling in Inquirer Letter to the Editor
 
Facebook Page “Eastwind Journals(no. 200)
http://www.sisterraquel.com/2016/12/doh-yields
 
By Bernie V. Lopez
eastwindreplyctr@gmail.com
Philippine Daily Inquirer Opinion Writer on Geopolitics
 
Permission is granted to re-publish with credits and notification.
Disclaimer – the views in this article are the author’s alone.
Unsubscribe anytime by email request.
 
Philippine Department of Health (DOH) Secretary Dr. Paulyn Ubial, newly appointed by President Duterte, was, initially against the use of the dengue vaccine Dengvaxia, produced by SANOFI, but changed her mind after the House Appropriations Committee threatened to reduce her department budget, as reported by the National Committee on Urban Pest Control (NCUPC). Duterte has alerted his agencies – the DENR, DOH, DA, and DBM to act on the NCUPC reports, but there are still no reactions as of this writing. SANOFI’s reply to the author’s Letter to the Inquirer Editor accusing it of meddling (December 10, 2016) is shown below.
 
CONTINUED

Dengvaxia is manufactured by Sanofi, a giant French multinational. According to the Scientific-American, Dengvaxia is not a total cure. It simply reduces “the chances of developing the disease by about 60%”. Also, it is “approved for use (only) in people 9 to 45 years old. If it is not safe for certain ages, then its entire safety is questionable. Sanofi’s claim that it is ‘safe’ based on 3 phases of clinical tests, whose details were undisclosed, is questionable. The Food and Drug Administration (FDA) must make the tests, not the makers.
 
Dengvaxia, a worldwide monopoly, costs a staggering Php3,000 to Php5,000 per person. Sanofi has an ingenious marketing strategy for such a highway robbery. They sell to Third World governments which are easy to ‘convince’ to allocate big budgets. Thus, the DOH has a whopping Php3 billion vaccine program. To complete the stranglehold, Sanofi has no local distributors and deals directly with DOH, says NCUPC. The P3-billion DOH dengue program targets mostly just Grade Four students. How about the rest? More budget?
 
How a foreign multinational has so much power to influence government health policies is appalling. So far, Mexico, Brazil, and the Philippines are the first victims, with India coming up next. In the US, there are many vaccine controversies. (Read more – 1-pre-school, 2-baby-dies, 3-respiratory, 4-cant-be-sued.) 
 
Environmentalists argue that attacking the mosquito is cheaper and more effective than attacking the virus with a questionable vaccine. Local fumigants cost as little as Php600 per barangay, like the one offered by Mapecon.
 
Sanofi also has tentacles in the FDA, which approved the Dengvaxia license in a midnight decision just before the 2016 elections, says NCUPC. Tests normally take years. Does our FDA approve without tests if the US FDA approves, not knowing that it is also controlled by pharmaceutical giants? 
 
We are calling on President Duterte to investigate the congressional blackmail, and to compel the DOH to suspend the use of Dengvaxia until further studies and tests. Our health decisions must be made by us, not by foreign multinationals looking for sudden windfalls.
 
Bernie V. Lopez eastwindreplyctr@gmail.com
 
********************
VACCINE MAKER SANOFI REPLIES TO THE ABOVE ARTICLE
As Published in a Letter to the Inquirer Editor
http://www.sisterraquel.com/2016/12/sanofi
 
*******************
POWERFUL VIDEO ON THE DANGERS OF VACCINES
http://vaccineliberationarmy.com/2016/12/17/laura-hayes-age-autismmother-injured-children-fabulous-speaker/
 
****************************** 
BREAKING NEWS – IT’S OFFICIAL, U.S. RECESSION IS HERE
MANY ECONOMIC ANALYSTS SAY
IT IS NOT JUST RECESSION BUT TOTAL COLLAPSE
AND SOONER THAN WE THINK.
http://www.marketoracle.co.uk/Article57851.html

No comments: